^
Association details:
| Biomarker: | APC mutation |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
Published date:
07/17/2020
Excerpt:
This open‐label, multi‐center, and single‐arm phase II study evaluated the efficacy of dasatinib for patients with metastatic GIST who had failed imatinib and sunitinib therapy. The primary endpoint was PFS at 3 months of dasatinib therapy...APC and/or TP53 mutation was only detected in patients with PFS ≥ 3 months.
DOI:
10.1002/cam4.3319
Trial ID:
